Osteoporosis, PostmenopausalNCT02884401
Peri-implant Bone Changes in Post-menopausal Osteoporotic Women
A study testing Dental implant placement (Straumann® Bone Level Tapered, BLT, Roxolid® SLActive®) in people with Osteoporosis, Postmenopausal, run by Queen Mary University of London at 1 site in United Kingdom.
Trial summary
This is a prospective case series study aiming to evaluate the effect of post-menopausal osteoporosis on the jaw bone around dental implants with a modified titanium surface. The study consists of 8 visits that will be performed within a minimum period of 15 months. Read more about this study
- Who is it for?
- Ages 50 years and older, women only
- Conditions the study is for
- Osteoporosis, Postmenopausal
- What is being tested?
- Dental implant placement (Straumann® Bone Level Tapered, BLT, Roxolid® SLActive®)
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 27 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- Sep 2016to 30 Aug 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Participants must present a diagnosis of osteoporosis based on DXA measurement of the bone mineral density at the femur neck and/or total hip and/or lumbar spine (T value 2.5 SD or more below the young female adult mean) within the past 24 months.
- Not in treatment with anti-resorptive agents (like bisphosphonates and denosumab) for more than 4 consecutive years, in order to reduce the risk of medication-related osteonecrosis of the jaws (Lo et al., 2010).
- ≥ 50 years old.
- In self-reported menopause, defined as the permanent cessation of ovulation, for at least one year (Soules et al., 2001).
- Edentulous area involving a maximum of two teeth (wisdom teeth and second molars are excluded) and presenting at least one neighbouring tooth (e.g. gap in the area of a second premolar and first molar, with first premolar in place).
- Residual alveolar width ≥ 4 mm (Milinkovic and Cordaro, 2014), residual alveolar height >8 mm, enough inter-arch space for a crown (at least 5 mm) and a minimum distance of 7 mm from the adjacent teeth (Shah and Lum, 2008). The width and height will be confirmed after x-ray examination in Visit 2.
Show all 9Show fewer
- Possibility to restore a functional occlusion with a minimum of four occlusal units (i.e. pairs of occluding posterior teeth).
- Willingness to replace the missing tooth/teeth with dental implants
- Registration with a GDP
Who cannot join
- On chronic treatment (i.e., two weeks or more) with any medication severely affecting oral status (e.g. participants with gingival hypertrophy caused by anti-epileptics, calcium antagonists, cyclosporine and other immunosuppressive) or bone metabolism (e.g. anticoagulant medications, long-standing steroid medications -i.e. equal or more 2.5mg of prednisolone a day taken for >3 months -, anticonvulsants, immunosuppressants).
- Affected by systemic diseases recognized to severely affect bone metabolism (e.g. Cushing's syndrome, Addison's disease, diabetes mellitus type 1, leukaemia, pernicious anaemia, malabsorption syndromes, chronic liver disease, rheumatoid arthritis).
- Knowingly affected by HIV or Hepatitis.
- History of local radiation therapy in the last five years.
- Affected by limited mental capacity or language skills such that study information cannot be understood, informed consent cannot be obtained, or simple instructions cannot be followed.
- Presenting an acute endodontic/periodontal lesion in the neighboring areas to the implant site.
Show all 13Show fewer
- Completely edentulous
- With evident severe atrophy of the alveolar ridge that could preclude an implant placement (e.g. sharp knife edge ridge)
- Severe bruxism or clenching habits
- Smokers of > 5 cigarettes a day.
- A daily alcohol intake >2 units/day.
- Other severe acute or chronic medical or psychiatric condition or laboratory abnormality which may increase the risk associated with trial participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this trial.
- Patients unable or not willing to return for follow-ups.
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site
Centre for Oral Clinical Research, Institute of Dentistry, Barts Health, QMUL
London, E1 2AD
About this study
Official title: Radiographic Peri-implant Alveolar Bone Changes in Post-menopausal Osteoporotic Women
This is a prospective case series study aiming to evaluate the effect of post-menopausal osteoporosis on the jaw bone around dental implants with a modified titanium surface. The study consists of 8 visits that will be performed within a minimum period of 15 months. Participants will be recruited from the Rheumatology Department and Radiology Department at Barts Health National Health Service (NHS) Trust.
Participants will include 20 post-menopausal osteoporotic women with a requirement of a tooth to be replaced. The main objective of this study is to radiographically compare alveolar (jaw) bone changes in width and height after the placement of a dental implant with a hydrophilic (SLActive) surface and 12 months after loading (placement of the crown) it in post-menopausal osteoporotic women.
Read the detailed description
This is a prospective case series study aiming to radiographically assess the changes in alveolar bone width and height after the placement of a SLActive implant (implant with a modified surface that should stimulate bone formation) and 12 months after loading it in post-menopausal osteoporotic women. The null hypothesis is: in post-menopausal osteoporotic women there are no significant changes in the peri-implant alveolar bone after the placement of a SLActive implant and 12 months after loading it in terms of width and height assessed by the use of CBCT images. The aim is to include 20 post-menopausal osteoporotic women with a requirement of a tooth to be replaced. However, considering a potential drop-out rate of 10%, the investigators have planned to increase the recruitment for this trial to 22 postmenopausal women. They will be recruited from the Rheumatology Department and Radiology Department at Barts Health NHS Trust, amongst those patients attending for a consultation with the osteoporosis specialist or for taking a Dual-energy X-ray absorptiometry (DXA) scan. Before starting the visit, post-menopausal women meeting the inclusion criteria will be asked by a study examiner if they agree to be quickly screened for the presence of an intercalate edentulous area (edentulous area in between the teeth)and if they may be interested in taking part into the study. If they agree, a quick dental examination will be performed by a study examiner (a qualified dentist) after the visit. The patients who would qualify for enrolment will receive information on the study, the patient information sheet and consent form, together with a letter to give to their General Dental Practitioner (GDP) in order to be referred to the Centre for Oral Clinical Research. The patients that do not qualify for enrolment will receive a report of the oral screening in case they require dental treatments.
Once the referral letter arrives at the Centre for Oral Clinical Research, Barts Health, the patient will be contacted to answer any further question and to book an appointment to attend the enrolment visit, should they wish.
The study consists of 8 visits that will be performed over a minimum period of 15 months at the Centre for Oral Clinical Research at the School of Dentistry of Queen Mary University of London (QMUL):
- Enrollment visit:
- Signing of informed consent;
- Recording of any concomitant medication;
- Confirmation of participant eligibility pertaining to the presence of an intercalate single edentulous area fulfilling the inclusion criteria (wisdom teeth and second molars excluded)
- Basic Periodontal Examination (BPE) recording;
- Clinical measurement of the periodontal parameter in the teeth adjacent to the area where the implant will be placed (Probing pocket Depth, PPD; Recession, REC; Plaque Index, PI; Bleeding on Probing, BOP)
- Exit participant if not eligible, arrangement for full-mouth debridement treatment outside the study protocol (if needed) and refer to GDP for other dental problems (such as caries and endodontic infections). If the patient agrees, a letter will be sent to the General Practitioner (GP) to inform about the participation in the study.
- Full-mouth debridement(within 90 days from enrolment):
- Recording of any Adverse Event (AE) or concomitant medication;
- Oral hygiene instructions and supra and sub gingival debridement of all teeth (as necessary) using ultrasonic and hand instruments as indicated. Local anaesthesia may be used as required to ensure pain control for the participant. In case a participant requires further periodontal treatment, this will be arranged outside the study protocol. No implant will be placed until a condition of periodontal health (no pockets ≥5 mm) will be reached.
- In order to plan the implant placement and according to the clinician's judgment and the complexity of the case, either a Cone Bean Computed Tomography (CBCT) scan or a peri-apical intra-oral x-ray, limited at the area of the implant placement, will be taken.
- Implant placement (within 120 days from visit 2):
- Recording of any AE or concomitant medication;
- Implant placement. If required, simultaneous horizontal guided regeneration (GBR) of the alveolar bone with a collagen membrane (Collprotect®, Botiss®, Zossen, Germany) and a bovine osteoconductive graft (Cerabone, Botiss®, Zossen, Germany) will be performed;
- Recording of maximum torque at placement;
- Healing cap screwed for semi-submerged healing;
- Resonance frequency analysis;
- Standardized CBCT scan limited to the implant area No sinus lift cases will be taken into consideration.
- Suture removal (7 days + 3 days from Visit 3):
- Recording of any AE or concomitant medication;
- Clinical evaluation of soft tissue healing (visual inspection of the surgical site and report of any complication);
- Suture removal;
- Resonance frequency analysis;
- Standardized CBCT scan limited to the implant area (if not performed on the day of implant placement).
- Implant impression (6 weeks ± 7 days from Visit 3):
- Recording of any AE or concomitant medication;
- Implant impression;
- Resonance frequency analysis. In case horizontal GBR is performed simultaneously to implant placement, the implant impression will be performed 11 weeks (+7 days) after implant placement.
- Implant loading (8 weeks ± 7 days from Visit 3):
- Recording of any AE or concomitant medication;
- Clinical measurement of the periodontal parameter in the teeth adjacent to the implant (PPD, REC, PI, BOP);
- Implant loading and occlusion control;
- Resonance frequency analysis;
- Peri-apical X-ray In case GBR is performed simultaneously to implant placement, the implant impression will be performed 12 weeks (+7 days) after implant placement.
- 6-months follow-up (6 months ± 14 days from Visit 6):
- Recording of any AE or concomitant medication;
- Clinical measurement of the periodontal parameter in the teeth adjacent to the implant (PPD, REC, PI, BOP) and on the implant
- Polish and oral hygiene instructions;
- Resonance frequency analysis;
- 12-months follow-up (12 months ± 14 days from Visit 6):
- Recording of any AE or concomitant medication;
- Clinical measurement of the periodontal parameter in the teeth adjacent to the implant (PPD, REC, PI, BOP) and on the implant;
- Polish and oral hygiene instructions;
- Resonance frequency analysis;
- CBCT scan and evaluation of implant survival and success. Photos of the teeth/implant may be taken to facilitate case documentation. The photos will be strictly limited to the implant/teeth area so that subjects will not be identifiable.
At study completion, a letter will be sent to the patient's GDP to inform about the treatments provided and highlight any need for further treatments.
- Conditions
- Osteoporosis, Postmenopausal
- Being tested
- Dental implant placement (Straumann® Bone Level Tapered, BLT, Roxolid® SLActive®)
- Medical subject headings
- Osteoporosis, Postmenopausal
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Dental implant placement (Straumann® Bone Level Tapered, BLT, Roxolid® SLActive®)Device
A tapered bone level implant (Straumann® BLT Roxolid® SLActive®, Basel, Switzerland) will be placed according to the manufactures guidelines trying to achieve primary stability in the correct prosthetic position
| Study group | Role | What they receive |
|---|---|---|
| osteoporotic women with a missing tooth | Other | Post-menopausal osteoporotic women with a missing tooth and willing to replace it with a dental implant Receives: Device: Dental implant placement (Straumann® Bone Level Tapered, BLT, Roxolid® SLActive®) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Changes in peri-implant horizontal and vertical alveolar bone
The peri-implant alveolar bone changes in height and width (in mm) will be assessed with the use of a CBCT scan after the implant placement (+10 days) and 12 months post loading (± 14 days). A single calibrated examiner will take all the measurements 3 times and the average value will be recorded. All measurements will be calculated with a 0.1 mm precision level.
Measured: After implant placement (+10 days) and 12 months after implant loading (± 14 days)
Secondary outcomes (2)
changes in implant stability measured with resonance frequency analysis
Resonance frequency analysis will be used to evaluate implant stability. Implant stability quotient (ISQ) will be recorded after implant placement, suture removal (7 days + 3 days after implant placement), implant impression (6 weeks ± 7 days after implant placement), implant loading (8 weeks ± 7 days after implant placement), at 6 months- (± 14 days) and 12 months- follow ups.
Measured: at implant placement, suture removal (7 days + 3 days after implant placement), implant impression (6 weeks ± 7 days after implant placement), implant loading (8 weeks ± 7 days after implant placement), at 6 months- (± 14 days) and 12 months- follow ups.
Implant success
Buser et al (1990) criteria will be used to evaluate implant success 12 months after loading (± 14 days)
Measured: 12 months after loading (± 14 days)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Aug 2016 (estimated)
- Study startSep 2016
- Primary completion15 Mar 2022
- Study completion30 Aug 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (7)Papers the sponsor has linked to this study.
- Other trials for Osteoporosis, PostmenopausalStudies of the same condition, open and under way.
- More trials run by Queen Mary University of LondonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 27 participants (actual)
Sponsor and investigators
- Lead sponsor
- Queen Mary University of London
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Nikolaos Donos, Prof, Principal investigator, Queen Mary University of London
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02884401
- Sponsor's protocol ID
- 010890
- Status last verified
- Feb 2022
- First submitted
- 7 Jun 2016
- Last updated
- 10 Nov 2022
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- No
Publications
Buser D, Broggini N, Wieland M, Schenk RK, Denzer AJ, Cochran DL, Hoffmann B, Lussi A, Steinemann SG. Enhanced bone apposition to a chemically modified SLA titanium surface. J Dent Res. 2004 Jul;83(7):529-33. doi: 10.1177/154405910408300704.
PubMed 15218041Calciolari E, Donos N, Park JC, Petrie A, Mardas N. A systematic review on the correlation between skeletal and jawbone mineral density in osteoporotic subjects. Clin Oral Implants Res. 2016 Apr;27(4):433-42. doi: 10.1111/clr.12597. Epub 2015 Apr 12.
PubMed 25864584Dao TT, Anderson JD, Zarb GA. Is osteoporosis a risk factor for osseointegration of dental implants? Int J Oral Maxillofac Implants. 1993;8(2):137-44.
PubMed 8359868Donos N, Hamlet S, Lang NP, Salvi GE, Huynh-Ba G, Bosshardt DD, Ivanovski S. Gene expression profile of osseointegration of a hydrophilic compared with a hydrophobic microrough implant surface. Clin Oral Implants Res. 2011 Apr;22(4):365-72. doi: 10.1111/j.1600-0501.2010.02113.x.
PubMed 21561478Lang NP, Salvi GE, Huynh-Ba G, Ivanovski S, Donos N, Bosshardt DD. Early osseointegration to hydrophilic and hydrophobic implant surfaces in humans. Clin Oral Implants Res. 2011 Apr;22(4):349-56. doi: 10.1111/j.1600-0501.2011.02172.x.
PubMed 21561476Mardas N, Schwarz F, Petrie A, Hakimi AR, Donos N. The effect of SLActive surface in guided bone formation in osteoporotic-like conditions. Clin Oral Implants Res. 2011 Apr;22(4):406-15. doi: 10.1111/j.1600-0501.2010.02094.x. Epub 2011 Feb 8.
PubMed 21303420Elena C, Nikos M, Iro P, Sara T, Nikolaos D. Radiographic Peri-Implant Bone Changes in Osteoporotic Women Treated With a Ti-Zr, Bone Level Tapered Implant With a Hydrophilic Surface: A 12-Month Prospective Case-Series. Clin Oral Implants Res. 2025 Oct;36(10):1234-1247. doi: 10.1111/clr.14469. Epub 2025 Jul 8.
PubMed 40625220
Study at a glance
From the registry record, last updated by the sponsor on 10 Nov 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Radiographic Peri-implant Alveolar Bone Changes in Post-menopausal Osteoporotic Women
- ClinicalTrials.gov ID
- NCT02884401
- Acronym / sponsor ID
- 010890
- Conditions
- Osteoporosis, Postmenopausal
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 27 participants (actual)
- Lead sponsor
- Queen Mary University of LondonUniversity, hospital or other
- Study start
- Sep 2016 (actual)
- Primary completion
- 15 Mar 2022 (actual)
- Study completion
- 30 Aug 2022 (actual)
- First posted
- 31 Aug 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a prospective case series study aiming to evaluate the effect of post-menopausal osteoporosis on the jaw bone around dental implants with a modified titanium surface. The study consists of 8 visits that will be performed within a minimum period of 15 months. Participants will be recruited from the Rheumatology Department and Radiology Department at Barts Health National Health Service (NHS) Trust.
Participants will include 20 post-menopausal osteoporotic women with a requirement of a tooth to be replaced. The main objective of this study is to radiographically compare alveolar (jaw) bone changes in width and height after the placement of a dental implant with a hydrophilic (SLActive) surface and 12 months after loading (placement of the crown) it in post-menopausal osteoporotic women.
Detailed description
This is a prospective case series study aiming to radiographically assess the changes in alveolar bone width and height after the placement of a SLActive implant (implant with a modified surface that should stimulate bone formation) and 12 months after loading it in post-menopausal osteoporotic women. The null hypothesis is: in post-menopausal osteoporotic women there are no significant changes in the peri-implant alveolar bone after the placement of a SLActive implant and 12 months after loading it in terms of width and height assessed by the use of CBCT images. The aim is to include 20 post-menopausal osteoporotic women with a requirement of a tooth to be replaced. However, considering a potential drop-out rate of 10%, the investigators have planned to increase the recruitment for this trial to 22 postmenopausal women. They will be recruited from the Rheumatology Department and Radiology Department at Barts Health NHS Trust, amongst those patients attending for a consultation with the osteoporosis specialist or for taking a Dual-energy X-ray absorptiometry (DXA) scan. Before starting the visit, post-menopausal women meeting the inclusion criteria will be asked by a study examiner if they agree to be quickly screened for the presence of an intercalate edentulous area (edentulous area in between the teeth)and if they may be interested in taking part into the study. If they agree, a quick dental examination will be performed by a study examiner (a qualified dentist) after the visit. The patients who would qualify for enrolment will receive information on the study, the patient information sheet and consent form, together with a letter to give to their General Dental Practitioner (GDP) in order to be referred to the Centre for Oral Clinical Research. The patients that do not qualify for enrolment will receive a report of the oral screening in case they require dental treatments.
Once the referral letter arrives at the Centre for Oral Clinical Research, Barts Health, the patient will be contacted to answer any further question and to book an appointment to attend the enrolment visit, should they wish.
The study consists of 8 visits that will be performed over a minimum period of 15 months at the Centre for Oral Clinical Research at the School of Dentistry of Queen Mary University of London (QMUL):
- Enrollment visit:
- Signing of informed consent;
- Recording of any concomitant medication;
- Confirmation of participant eligibility pertaining to the presence of an intercalate single edentulous area fulfilling the inclusion criteria (wisdom teeth and second molars excluded)
- Basic Periodontal Examination (BPE) recording;
- Clinical measurement of the periodontal parameter in the teeth adjacent to the area where the implant will be placed (Probing pocket Depth, PPD; Recession, REC; Plaque Index, PI; Bleeding on Probing, BOP)
- Exit participant if not eligible, arrangement for full-mouth debridement treatment outside the study protocol (if needed) and refer to GDP for other dental problems (such as caries and endodontic infections). If the patient agrees, a letter will be sent to the General Practitioner (GP) to inform about the participation in the study.
- Full-mouth debridement(within 90 days from enrolment):
- Recording of any Adverse Event (AE) or concomitant medication;
- Oral hygiene instructions and supra and sub gingival debridement of all teeth (as necessary) using ultrasonic and hand instruments as indicated. Local anaesthesia may be used as required to ensure pain control for the participant. In case a participant requires further periodontal treatment, this will be arranged outside the study protocol. No implant will be placed until a condition of periodontal health (no pockets ≥5 mm) will be reached.
- In order to plan the implant placement and according to the clinician's judgment and the complexity of the case, either a Cone Bean Computed Tomography (CBCT) scan or a peri-apical intra-oral x-ray, limited at the area of the implant placement, will be taken.
- Implant placement (within 120 days from visit 2):
- Recording of any AE or concomitant medication;
- Implant placement. If required, simultaneous horizontal guided regeneration (GBR) of the alveolar bone with a collagen membrane (Collprotect®, Botiss®, Zossen, Germany) and a bovine osteoconductive graft (Cerabone, Botiss®, Zossen, Germany) will be performed;
- Recording of maximum torque at placement;
- Healing cap screwed for semi-submerged healing;
- Resonance frequency analysis;
- Standardized CBCT scan limited to the implant area No sinus lift cases will be taken into consideration.
- Suture removal (7 days + 3 days from Visit 3):
- Recording of any AE or concomitant medication;
- Clinical evaluation of soft tissue healing (visual inspection of the surgical site and report of any complication);
- Suture removal;
- Resonance frequency analysis;
- Standardized CBCT scan limited to the implant area (if not performed on the day of implant placement).
- Implant impression (6 weeks ± 7 days from Visit 3):
- Recording of any AE or concomitant medication;
- Implant impression;
- Resonance frequency analysis. In case horizontal GBR is performed simultaneously to implant placement, the implant impression will be performed 11 weeks (+7 days) after implant placement.
- Implant loading (8 weeks ± 7 days from Visit 3):
- Recording of any AE or concomitant medication;
- Clinical measurement of the periodontal parameter in the teeth adjacent to the implant (PPD, REC, PI, BOP);
- Implant loading and occlusion control;
- Resonance frequency analysis;
- Peri-apical X-ray In case GBR is performed simultaneously to implant placement, the implant impression will be performed 12 weeks (+7 days) after implant placement.
- 6-months follow-up (6 months ± 14 days from Visit 6):
- Recording of any AE or concomitant medication;
- Clinical measurement of the periodontal parameter in the teeth adjacent to the implant (PPD, REC, PI, BOP) and on the implant
- Polish and oral hygiene instructions;
- Resonance frequency analysis;
- 12-months follow-up (12 months ± 14 days from Visit 6):
- Recording of any AE or concomitant medication;
- Clinical measurement of the periodontal parameter in the teeth adjacent to the implant (PPD, REC, PI, BOP) and on the implant;
- Polish and oral hygiene instructions;
- Resonance frequency analysis;
- CBCT scan and evaluation of implant survival and success. Photos of the teeth/implant may be taken to facilitate case documentation. The photos will be strictly limited to the implant/teeth area so that subjects will not be identifiable.
At study completion, a letter will be sent to the patient's GDP to inform about the treatments provided and highlight any need for further treatments.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| osteoporotic women with a missing tooth | Other | Device: Dental implant placement (Straumann® Bone Level Tapered, BLT, Roxolid® SLActive®)Post-menopausal osteoporotic women with a missing tooth and willing to replace it with a dental implant |
Who may qualify
- Ages
- 50 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- Participants must present a diagnosis of osteoporosis based on DXA measurement of the bone mineral density at the femur neck and/or total hip and/or lumbar spine (T value 2.5 SD or more below the young female adult mean) within the past 24 months.
- Not in treatment with anti-resorptive agents (like bisphosphonates and denosumab) for more than 4 consecutive years, in order to reduce the risk of medication-related osteonecrosis of the jaws (Lo et al., 2010).
- ≥ 50 years old.
- In self-reported menopause, defined as the permanent cessation of ovulation, for at least one year (Soules et al., 2001).
- Edentulous area involving a maximum of two teeth (wisdom teeth and second molars are excluded) and presenting at least one neighbouring tooth (e.g. gap in the area of a second premolar and first molar, with first premolar in place).
Key exclusion criteria (13 listed)
- On chronic treatment (i.e., two weeks or more) with any medication severely affecting oral status (e.g. participants with gingival hypertrophy caused by anti-epileptics, calcium antagonists, cyclosporine and other immunosuppressive) or bone metabolism (e.g. anticoagulant medications, long-standing steroid medications -i.e. equal or more 2.5mg of prednisolone a day taken for >3 months -, anticonvulsants, immunosuppressants).
- Affected by systemic diseases recognized to severely affect bone metabolism (e.g. Cushing's syndrome, Addison's disease, diabetes mellitus type 1, leukaemia, pernicious anaemia, malabsorption syndromes, chronic liver disease, rheumatoid arthritis).
- Knowingly affected by HIV or Hepatitis.
- History of local radiation therapy in the last five years.
- Affected by limited mental capacity or language skills such that study information cannot be understood, informed consent cannot be obtained, or simple instructions cannot be followed.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Dental implant placement (Straumann® Bone Level Tapered, BLT, Roxolid® SLActive®)A tapered bone level implant (Straumann® BLT Roxolid® SLActive®, Basel, Switzerland) will be placed according to the manufactures guidelines trying to achieve primary stability in the correct prosthetic position | Device | osteoporotic women with a missing tooth |
Primary outcome
Changes in peri-implant horizontal and vertical alveolar bone
Time frame: After implant placement (+10 days) and 12 months after implant loading (± 14 days)
The peri-implant alveolar bone changes in height and width (in mm) will be assessed with the use of a CBCT scan after the implant placement (+10 days) and 12 months post loading (± 14 days). A single calibrated examiner will take all the measurements 3 times and the average value will be recorded. All measurements will be calculated with a 0.1 mm precision level.
2 secondary outcomes
changes in implant stability measured with resonance frequency analysis
Time frame: at implant placement, suture removal (7 days + 3 days after implant placement), implant impression (6 weeks ± 7 days after implant placement), implant loading (8 weeks ± 7 days after implant placement), at 6 months- (± 14 days) and 12 months- follow ups.
Implant success
Time frame: 12 months after loading (± 14 days)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Nov 2022.
- Background: PubMed 15218041Buser D, Broggini N, Wieland M, Schenk RK, Denzer AJ, Cochran DL, Hoffmann B, Lussi A, Steinemann SG. Enhanced bone apposition to a chemically modified SLA titanium surface. J Dent Res. 2004 Jul;83(7):529-33. doi: 10.1177/154405910408300704.
- Background: PubMed 25864584Calciolari E, Donos N, Park JC, Petrie A, Mardas N. A systematic review on the correlation between skeletal and jawbone mineral density in osteoporotic subjects. Clin Oral Implants Res. 2016 Apr;27(4):433-42. doi: 10.1111/clr.12597. Epub 2015 Apr 12.
- Background: PubMed 8359868Dao TT, Anderson JD, Zarb GA. Is osteoporosis a risk factor for osseointegration of dental implants? Int J Oral Maxillofac Implants. 1993;8(2):137-44.
- Background: PubMed 21561478Donos N, Hamlet S, Lang NP, Salvi GE, Huynh-Ba G, Bosshardt DD, Ivanovski S. Gene expression profile of osseointegration of a hydrophilic compared with a hydrophobic microrough implant surface. Clin Oral Implants Res. 2011 Apr;22(4):365-72. doi: 10.1111/j.1600-0501.2010.02113.x.
- Background: PubMed 21561476Lang NP, Salvi GE, Huynh-Ba G, Ivanovski S, Donos N, Bosshardt DD. Early osseointegration to hydrophilic and hydrophobic implant surfaces in humans. Clin Oral Implants Res. 2011 Apr;22(4):349-56. doi: 10.1111/j.1600-0501.2011.02172.x.
- Background: PubMed 21303420Mardas N, Schwarz F, Petrie A, Hakimi AR, Donos N. The effect of SLActive surface in guided bone formation in osteoporotic-like conditions. Clin Oral Implants Res. 2011 Apr;22(4):406-15. doi: 10.1111/j.1600-0501.2010.02094.x. Epub 2011 Feb 8.
- Derived from this study: PubMed 40625220Elena C, Nikos M, Iro P, Sara T, Nikolaos D. Radiographic Peri-Implant Bone Changes in Osteoporotic Women Treated With a Ti-Zr, Bone Level Tapered Implant With a Hydrophilic Surface: A 12-Month Prospective Case-Series. Clin Oral Implants Res. 2025 Oct;36(10):1234-1247. doi: 10.1111/clr.14469. Epub 2025 Jul 8.
- Individual participant dataSharing planned: No
Related trials for Osteoporosis, Postmenopausal
Active, not recruitingObservational study
The Impact of Osteosarcopenia on Falls, Kinesiophobia, and Quality of Life in Postmenopausal Women
Osteosarcopenia, Sarcopenia
Not yet recruitingPhase 4
Romosozumab and Denosumab Combination Therapy for Osteoporosis
Postmenopausal Osteoporosis
Not yet recruiting
Effects of Sensorimotor Balance Training vs Digitally Augmented Core Stabilization in Women With Osteoporosis
Postmenopausal Osteoporosis
Active, not recruitingPhase 4
Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone
Osteoporosis, Postmenopausal
RecruitingPhase 4
Combined Anabolic Therapy
Osteoporosis, Postmenopausal, Osteoporosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Nikolaos Donos, Prof principal investigator
Queen Mary University of London
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Dental implant placement (Straumann® Bone Level Tapered, BLT, Roxolid® SLActive®) in people with Osteoporosis, Postmenopausal, run by Queen Mary University of London at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Nov 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Changes in peri-implant horizontal and vertical alveolar bone (time frame: After implant placement (+10 days) and 12 months after implant loading (± 14 days)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02884401, which also lists 7 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Nov 2022.